← Leaderboards
Christine Elissa Eyler
Duke University
$1,102,247
Attributed
$1,181,605
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $399.5K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,181,605 · 3
By mechanism
K08$962,266 · 1
R21$158,716 · 1
F30$60,623 · 1
Top collaborators
- Chang-Lung Lee1 shared
Most similar at Duke University
Same institution · by research overlap
- John P Chute$16,426,438
- Nelson J. Chao$27,968,804
- Christopher Dennis Kassotis$1,816,350
- Eric M Darling$2,880,684
- Katherine Garman$6,156,572
Others in their field
Top investigators on “Foundations”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Mitchell J Malone · Texas A&M Research Foundation$353,400,900
- Gary D Acton · University Of California-Davis$320,373,312
- George R Seage · Abt Associates, Inc.$281,069,277
- Everette D Joseph · Howard University$268,880,223
- Valerie Koch · University Corporation For Atmospheric Res$265,601,376
Research focus
FoundationsPhenotypeCellsResponseMalignant NeoplasmsSpecimenLaboratoriesResistanceTreatment StrategyTrainingNeoplastic CellTumorRadiation TherapyDiagnosisEffectivenessDesignEpigenetic ProcessVariantCrispr/Cas TechnologyOrganoidsDrug SensitivityDrug ScreeningCareer DevelopmentCytotoxic Chemotherapy
Grant awards (7)
Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform$240,767
K08 · FY2025 · CA · contact PI
Epigenetic mechanisms of intestinal stem cell fate conversion in response to severe radiation injury$158,716
R21 · FY2025 · AI
Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform$239,693
K08 · FY2024 · CA · contact PI
Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform$240,840
K08 · FY2023 · CA · contact PI
Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform$240,966
K08 · FY2022 · CA · contact PI
Targeting Brain Tumor Stem Cells$29,356
F30 · FY2010 · NS · contact PI
Targeting Brain Tumor Stem Cells$31,267
F30 · FY2009 · NS · contact PI